STOCK TITAN

IRIDEX (IRIX) SEC Filings, Jun-Sep 2026

IRIX NASDAQ

Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.

Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.

Rhea-AI Summary

IRIDEX Corporation (IRIX) reports that Nasdaq has notified it of non-compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, after the stock traded below that level for the last 30 consecutive business days.

Under Nasdaq Listing Rule 5810(c)(3)(A), IRIDEX has a 180-day Cure Period to February 23, 2027 to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it meets other Nasdaq initial listing standards (apart from bid price) and commits to cure the deficiency, including potentially via a reverse stock split, it may receive an additional 180 days. If compliance is not regained, the common stock may be delisted, subject to an appeal process. The company states that the notice has no immediate impact on trading, business operations, or SEC reporting and that it is monitoring its stock price and evaluating options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
current report
-
Rhea-AI Summary

IRIDEX CORP (IRIX) reported that Chief Financial Officer Romeo R. Dizon purchased shares of the company’s Common Stock. On 2026-08-24, he bought 1,300 shares at $0.7488 per share and 5,368 shares at $0.7499 per share in open-market or private transactions. Following these purchases, his reported direct ownership increased to 169,952 Common Stock shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation (IRIX) reported lower revenue but a smaller net loss for the three and six months ended July 4, 2026. Quarterly revenue was $12.6 million, down 7.4% year over year, with Cyclo G6 glaucoma products growing while retina product revenue declined. Gross margin was 34.2%, slightly below 34.5% a year earlier, as higher manufacturing and tariff-related costs weighed on profitability. The company posted a quarterly net loss of $1.3 million (–$0.07 per share), compared with a $1.0 million loss in the prior-year quarter; year-to-date loss improved to $1.8 million from $2.7 million.

Cash and cash equivalents were $4.7 million with working capital of $10.8 million, against total liabilities of $23.6 million, including a $3.8 million convertible note. Deferred revenue totaled $8.2 million, largely from a 10‑year exclusive distribution arrangement with Topcon, which accounted for about 30–33% of revenue. Management highlights ongoing cost-control initiatives, a continued shift to lower-cost contract manufacturers, and macroeconomic and geopolitical uncertainty affecting capital equipment demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.83%
Tags
quarterly report
Rhea-AI Summary

IRIDEX CORP (IRIX) reported second quarter 2026 revenue of $12.6 million, down 7% from $13.6 million a year earlier, as weaker retina sales offset growth in glaucoma products. Retina product revenue fell to $6.5 million from $8.0 million, while Cyclo G6 product family revenue rose 19% to $3.9 million, driven by higher probe volumes.

Gross margin was stable at 34.2% versus 34.5% last year. Operating expenses declined 5% to $5.3 million on lower general and administrative costs, but net loss widened to $1.3 million (–$0.07 per share) from $1.0 million (–$0.06). Adjusted EBITDA moved to a loss of $0.4 million from a small profit. The company was operating cash-flow positive in the quarter and ended July 4, 2026 with $4.7 million in cash and cash equivalents.

IRIDEX reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects fiscal 2026 adjusted operating expenses of $19.0–$19.5 million. Management highlighted ongoing cost-transformation efforts, including shifting production to lower-cost contract manufacturers and relocating headquarters, which are intended to support long-term profitability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.83%
Tags
current report
-
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
current report
-
Rhea-AI Summary

Mercer Patrick reported acquisition or exercise transactions in this Form 4 filing.

IRIDEX CORP President and CEO Patrick Mercer received equity awards on July 10, 2026, including 100,000 restricted stock units, 100,000 performance RSUs that vest if the share price reaches $2.50 for 30 consecutive trading days, and options for 200,000 shares at $1.10 per share. The RSUs and options vest as to one-third of the shares on July 10, 2027 and on each one-year anniversary thereafter, subject to continued service. Following these awards he directly holds 468,784 common shares, plus 100,000 performance units and 200,000 options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
insider
Rhea-AI Summary

IRIDEX CORP awarded its Chief Financial Officer, Romeo R. Dizon, equity-based compensation consisting of 30,000 restricted stock units (RSUs) and a stock option for 170,000 shares. Each RSU represents a contingent right to receive one share of common stock, vesting in three equal annual installments: one-third on July 10, 2027 and one-third on each of the next two anniversaries, subject to his continued service.

The option gives Dizon the right to purchase up to 170,000 shares of IRIDEX common stock at an exercise price of $1.10 per share and expires on July 10, 2033. Following these awards, he holds 163,284 shares of common stock directly, in addition to the newly granted stock option. These are compensation grants rather than open‑market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
insider
-
Rhea-AI Summary

Novel Inspiration International Co., Ltd., Xinpo Venture Capital Co., Ltd. and Shih‑Yao David Lin report a large investment position in Iridex Corp. common stock. As of July 10, 2026, Mr. Lin beneficially owns 6,738,238 shares, representing 29.92% of the common stock, including holdings through Novel Inspiration and Xinpo. Percentages are based on 17,406,518 shares outstanding as of May 11, 2026 plus 111,997 shares issued on July 7, 2026.

Novel Inspiration holds 600,000 shares of Series B Preferred Stock convertible into 3,000,000 common shares and a Convertible Promissory Note exchangeable into 400,000 additional Series B shares, convertible into 2,000,000 common shares, plus common shares issued as interest on the note. The note bears 12% annual interest, paid quarterly in stock under a pricing formula with a $0.21 per‑share floor; Iridex issued 87,949 shares on April 1, 2026 and 111,997 shares on July 7, 2026 as interest. Xinpo beneficially owns 1,186,809 common shares, about 6.77% of the class, acquired in open‑market purchases on the Nasdaq Capital Market for an aggregate $1,310,308.

The investor group states that it holds the securities for investment and plans to engage with Iridex’s board and management on business strategy, board composition and potential representation, operational initiatives, capital structure, and possible transactions, including mergers and acquisitions, balance sheet changes, dividends, share repurchases, or a going‑private transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
ownership
-
Rhea-AI Summary

IRIDEX CORP disclosed a non-cash equity transaction with a major shareholder. Novel Inspiration International Co., Ltd., a 10% owner, received 111,997 shares of common stock as a quarterly interest payment on a Convertible Promissory Note issued on March 19, 2025. After this issuance, Novel Inspiration directly beneficially owns 551,429 shares, which are also indirectly beneficially owned by Shih-Yao David Lin as the sole officer, director and stockholder of Novel Inspiration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

IRIDEX Corporation convened its 2026 annual meeting of stockholders on June 12, 2026 but immediately adjourned it without conducting any business. The meeting is scheduled to reconvene at 8:00 a.m. Pacific Time on July 10, 2026 at the company’s Mountain View, California headquarters.

The record date for voting remains April 17, 2026, and the proposals to be considered are unchanged. Proxies already submitted remain valid and will be voted at the reconvened meeting unless properly revoked, so stockholders who have already voted are not required to act again.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
current report

FAQ

How many IRIDEX (IRIX) SEC filings are available on StockTitan?

StockTitan tracks 98 SEC filings for IRIDEX (IRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRIDEX (IRIX)?

The most recent SEC filing for IRIDEX (IRIX) was filed on November 17, 2026.